Our Mission:
To develop drugs that target components of the ubiquitin system, based on our expanding proprietary knowledge.

Our Vision:
Proteologics aspires to become a fully integrated pharmaceutical company and a leader in the emerging field of the ubiquitin-related drugs.

Company Profile:
From Target Discovery to Drug Development
Proteologics identifies correlations between ubiquitin pathway components and pathological conditions. Once specific E3 targets are being selected and validated, we proceed to establishing proprietary technologies for the accelerated hit-to-lead drug discovery process. Proteologics' recognized competencies are built through a number of internal programs and partnerships, including strategic R&D collaborations with Glaxo Smith Kline (GSK) and Teva Pharmaceutical Industries Ltd.

Company Background:
Proteologics was founded in 1999 and is a public company traded on the Tel-Aviv Stock Exchange.